Janssen sued Mylan for allegedly inducing patent infringement through its proposed generic drug labels for a treatment of missed doses of Janssen's schizophrenia medication, Invega Trinza. The district court found in favor of Janssen, determining that Mylan would likely induce healthcare providers to infringe Janssen's patent and that Mylan failed to prove the patent was invalid. Mylan appealed this decision, arguing against the findings of induced infringement and nonobviousness of the patent. The Court of Appeals ultimately affirmed the district court's decision, finding Mylan's arguments unpersuasive on both issues.